Boston University Libraries OpenBU
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    •   OpenBU
    • BU Open Access Articles
    • BU Open Access Articles
    • View Item
    •   OpenBU
    • BU Open Access Articles
    • BU Open Access Articles
    • View Item

    Epigenetic treatment of neuropsychiatric disorders: autism and schizophrenia

    Thumbnail
    Date Issued
    2016-03-01
    Publisher Version
    10.1002/ddr.21295
    Author(s)
    Moos, Walter H.
    Maneta, Eleni
    Pinkert, Carl A.
    Irwin, Michael H.
    Hoffman, Michelle E.
    Faller, Douglas V.
    Steliou, Kosta
    Share to FacebookShare to TwitterShare by Email
    Export Citation
    Download to BibTex
    Download to EndNote/RefMan (RIS)
    Metadata
    Show full item record
    Embargoed until:
    Indefinite
    Permanent Link
    https://hdl.handle.net/2144/40859
    Version
    Accepted manuscript
    Citation (published version)
    Walter H Moos, Eleni Maneta, Carl A Pinkert, Michael H Irwin, Michelle E Hoffman, Douglas V Faller, Kosta Steliou. 2016. "Epigenetic treatment of neuropsychiatric disorders: autism and schizophrenia." Drug Development Research Volume 77, Issue 2, pp. 53 - 72. https://doi.org/10.1002/ddr.21295
    Abstract
    Neuropsychiatric disorders are a heterogeneous group of conditions that often share underlying mitochondrial dysfunction and biological pathways implicated in their pathogenesis, progression, and treatment. To date, these disorders have proven notoriously resistant to molecular-targeted therapies, and clinical options are relegated to interventional types, which do not address the core symptoms of the disease. In this review, we discuss emerging epigenetic-driven approaches using novel acylcarnitine esters (carnitinoids) that act on master regulators of antioxidant and cytoprotective genes and mitophagic pathways. These carnitinoids are actively transported, mitochondria-localizing, biomimetic coenzyme A surrogates of short-chain fatty acids, which inhibit histone deacetylase and may reinvigorate synaptic plasticity and protect against neuronal damage. We outline these neuroprotective effects in the context of treatment of neuropsychiatric disorders such as autism spectrum disorder and schizophrenia.
    Description
    Please note: this work is permanently embargoed in OpenBU. No public access is forecasted for this item. To request private access, please click on the locked Download file link and fill out the appropriate web form.
    Collections
    • MED: Medicine Papers [241]
    • Cancer Center Papers [12]
    • BU Open Access Articles [3866]

    Related items

    Showing items related by title, author, creator and subject.

    • Thumbnail

      A latent class analysis of parental bipolar disorder: examining associations with offspring psychopathology 

      Freed, Rachel D.; Tompson, Martha C.; Otto, Michael W.; Nierenberg, Andrew A.; Henin, Aude (ELSEVIER IRELAND LTD, 2015-12-15)
      Bipolar disorder (BD) is highly heterogeneous, and course variations are associated with patient outcomes. This diagnostic complexity challenges identification of patients in greatest need of intervention. Additionally, ...
    • Thumbnail

      Anger: the unrecognized emotion in emotional disorders 

      Cassiello-Robbins, Clair; Barlow, David H. (WILEY, 2016-03-01)
      Anger plays a prominent definitional role in some psychological disorders currently widely scattered across DSM‐5 categories (e.g., intermittent explosive disorder, borderline personality disorder). But the presence and ...
    • Thumbnail

      Development of an integrated cognitive behavioral therapy for anxiety and opioid use disorder: Study protocol and methods 

      McHugh, R. Kathryn; Votaw, Victoria R.; Barlow, David H.; Fitzmaurice, Garrett M.; Greenfield, Shelly F.; Weiss, Roger D. (ELSEVIER SCIENCE INC, 2017-09-01)
      Opioid use disorder is a highly disabling psychiatric disorder, and is associated with both significant functional disruption and risk for negative health outcomes such as infectious disease and fatal overdose. Even among ...

    Boston University
    Contact Us | Send Feedback | Help
     

     

    Browse

    All of OpenBUCommunities & CollectionsIssue DateAuthorsTitlesSubjectsThis CollectionIssue DateAuthorsTitlesSubjects

    Deposit Materials

    LoginNon-BU Registration

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Boston University
    Contact Us | Send Feedback | Help